GRPR and gastrointestinal stromal tumor: GRPR is also highly expressed in gastrointestinal stromal tumor (GIST) patients (~80%), so that NeoB could be a valuable potential drug candidate to treat such tumors that lack effective therapies when resistance to receptor tyrosine kinase (RTK) inhibitors occurs [25,26,27].